GlassScriptPhysician profile
Sarah Deline
NPI 1801254925
$11,652.61
in general payments reported to CMS, 2019-2025
44 companies · $2,175 in 2025
The $2,175 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $564 · 2022: $847 · 2023: $5,422 · 2024: $2,646 · 2025: $2,175.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,562 · Consulting Fee: $3,194 · Honoraria: $2,000 · Education: $282 · Travel and Lodging: $204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,562.32 |
| Consulting Fee | $3,194.00 |
| Honoraria | $2,000.00 |
| Education | $281.99 |
| Travel and Lodging | $204.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Apellis Pharmaceuticals, INC. | $2,356.62 | 2023 | Empaveli |
| Janssen Biotech, INC. | $2,300.21 | 2021-2025 | Erleada, Akeega, Rybrevant |
| G1 Therapeutics, INC. | $1,323.78 | 2023 | Cosela |
| Blueprint Medicines Corporation | $591.03 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $579.61 | 2021-2024 | Enhertu, Imfinzi, Lynparza |
| Seagen INC. | $381.69 | 2021-2023 | Tukysa, Padcev, Adcetris |
| Daiichi Sankyo INC. | $331.24 | 2021-2024 | Enhertu, Injectafer |
| Merck Sharp & Dohme LLC | $246.03 | 2023-2024 | Keytruda, Welireg, Reblozyl |
| E.R. Squibb & Sons, L.L.C. | $244.02 | 2022-2024 | Opdualag, Opdivo |
| Kite Pharma, INC. | $238.23 | 2023-2024 | |
| Exelixis INC. | $237.98 | 2023-2025 | Cabometyx |
| Regeneron Healthcare Solutions, INC. | $191.11 | 2023-2025 | Libtayo |
| Beigene USA, INC. | $176.97 | 2023-2024 | Brukinsa |
| Gilead Sciences, INC. | $165.73 | 2022-2024 | Trodelvy |
| Glaxosmithkline, LLC. | $165.63 | 2022-2024 | Ojjaara |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $161.37 | 2024 | Monoferric, Cosela |
| Aveo Pharmaceuticals, INC. | $153.28 | 2023-2024 | Fotivda |
| Astellas Pharma US INC | $150.41 | 2023-2025 | Vyloy, Xospata |
| Novartis Pharmaceuticals Corporation | $142.72 | 2023-2024 | |
| Jazz Pharmaceuticals INC. | $134.35 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $121.99 | 2021-2023 | |
| Eisai INC. | $117.31 | 2022-2024 | |
| Servier Pharmaceuticals LLC | $103.11 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $103.08 | 2022-2024 | Ninlaro, Alunbrig |
| Genentech USA, INC. | $101.85 | 2023-2024 | Tecentriq, Lunsumio, Columvi |
| Genzyme Corporation | $81.57 | 2023-2024 | |
| Pfizer INC. | $80.86 | 2023-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $74.92 | 2022-2023 | Imbruvica |
| Lilly USA, LLC | $70.04 | 2023-2024 | Verzenio, Jaypirca, Retevmo |
| Sobi, INC | $63.26 | 2024-2025 | |
| Amgen INC. | $61.17 | 2022-2023 | Kyprolis |
| Celgene Corporation | $61.01 | 2023-2024 | Pomalyst, Reblozyl |
| Tersera Therapeutics LLC | $59.38 | 2023-2024 | Zoladex, Xermelo |
| Stemline Therapeutics INC. | $46.28 | 2023-2024 | Orserdu |
| Array Biopharma INC | $36.95 | 2024 | Braftovi, Mektovi, Lorbrena |
| Taiho Oncology, INC. | $26.39 | 2025 | |
| Pharmaessentia USA Corporation | $24.06 | 2024 | Besremi |
| Rigel Pharmaceuticals, INC. | $24.03 | 2024 | Rezlidhia, Tavalisse |
| Genmab U.S., INC. | $23.93 | 2024 | Epkinly |
| Incyte Corporation | $23.73 | 2023 | Monjuvi, Zynyz, Pemazyre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.90 | 2024 | Gilotrif |
| Karyopharm Therapeutics INC. | $21.07 | 2023 | Xpovio |
| Cti Biopharma Corp. | $17.40 | 2023 | Vonjo |
| Puma Biotechnology, INC. | $14.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Deline listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.